A recent study showed that designer benzodiazepine use was linked to an increase in morbidity and mortality. Tools to discover the use of designer are available, most notably, enhanced drug testing. Read more here: https://lnkd.in/ecj_vWDa Aegis offers clinicians the ability to detect designer benzodiazepine use in their patients, which affords the opportunity to discuss further risk mitigation. Learn more today: https://lnkd.in/emXVQJ93 #AegisLabs #NPS #DesignerDrugs #OnePillCanKill #OverdosePrevention
Aegis Sciences Corporation’s Post
More Relevant Posts
-
Please reach out if you’d like to review this report with me!
Released today, Volume 6 of our Millennium Health Signals Report™ The “Fourth Wave”: The Rise of Stimulants and the Evolution of Polysubstance Use in America’s Fentanyl Crisis explores changes in the co-detection of prescription opioids, heroin, methamphetamine, and cocaine in fentanyl-positive urine specimens, and provides insight into recent trends in polysubstance use among people who use fentanyl. It also describes how urine drug test data tightly correlate with trends in fentanyl-related overdose deaths. https://ow.ly/GN6f50QGbhr
Methamphetamine Use Reaches All-Time High in People Who Use Fentanyl with No Signs of Slowing, Adding Fuel to U.S. Fentanyl Crisis
https://www.millenniumhealth.com
-
Important focus in Forbes on the #lifesaving #innovation that drives MDI Health in their mission to combat the epidemic of adverse drug reactions. #medicaltechnology #healthcare
A Potential Solution For The 4th Cause Of Death In The U.S.
forbes.com
-
Released today, Volume 6 of our Millennium Health Signals Report™ The “Fourth Wave”: The Rise of Stimulants and the Evolution of Polysubstance Use in America’s Fentanyl Crisis explores changes in the co-detection of prescription opioids, heroin, methamphetamine, and cocaine in fentanyl-positive urine specimens, and provides insight into recent trends in polysubstance use among people who use fentanyl. It also describes how urine drug test data tightly correlate with trends in fentanyl-related overdose deaths. https://ow.ly/GN6f50QGbhr
Methamphetamine Use Reaches All-Time High in People Who Use Fentanyl with No Signs of Slowing, Adding Fuel to U.S. Fentanyl Crisis
https://www.millenniumhealth.com
-
Please reach out if you would like to review this new data with me!
Released today, Volume 6 of our Millennium Health Signals Report™ The “Fourth Wave”: The Rise of Stimulants and the Evolution of Polysubstance Use in America’s Fentanyl Crisis explores changes in the co-detection of prescription opioids, heroin, methamphetamine, and cocaine in fentanyl-positive urine specimens, and provides insight into recent trends in polysubstance use among people who use fentanyl. It also describes how urine drug test data tightly correlate with trends in fentanyl-related overdose deaths. https://ow.ly/GN6f50QGbhr
Methamphetamine Use Reaches All-Time High in People Who Use Fentanyl with No Signs of Slowing, Adding Fuel to U.S. Fentanyl Crisis
https://www.millenniumhealth.com
-
Founder & Chairman of Private Medical -Internist, Science geek. Always curious. I like people who are smart, curious and skeptical.
𝚁𝚊𝚙𝚊𝚖𝚢𝚌𝚒𝚗 𝙶𝚘𝚎𝚜 𝚒𝚗𝚝𝚘 𝙲𝚕𝚒𝚗𝚒𝚌𝚊𝚕 𝚃𝚛𝚒𝚊𝚕𝚜 - 𝙵𝚘𝚛 𝙶𝚞𝚖 𝙳𝚒𝚜𝚎𝚊𝚜𝚎 For the longevity enthusiasts, this is a step down the road to understand safety and efficacy. The U.S. Food and Drug Administration (FDA) has approved Dr. Jonathan An from the UW Department of Oral Health Sciences to lead the first-ever study to evaluate rapamycin in older adults with periodontal disease.
UW periodontal study receives FDA approval for anti-aging drug use
dental.washington.edu
-
Drug reaction w/ eosinophilia & systemic symptoms (DRESS) is a complex, severe cutaneous adverse drug reaction that poses challenges for clinicians; this consensus is aimed at providing needed support in diagnosis, assessment, and treatment of patients with DRESS. https://ja.ma/3tVxSWO
Management of Adult Patients With Drug Reaction With Eosinophilia and Systemic Symptoms
jamanetwork.com
-
Today, Rare Disease Day 2024, represents a global effort towards awareness and equity in social opportunity, healthcare, and access to diagnosis and therapies for people living with a rare disease. 🧬 Rare diseases are not so rare: an estimated 1 in 20 people have a rare disease, and 2 out of 10 people know someone who has one. Personally, I have 3 rare diseases in my family - my dad, my sister and even my dog! None of those diseases has an indicated treatment. This is part of the reason that Rare Disease is a big passion area for me in my work. Rare diseases have emerged as a global public health priority and have been at the forefront of biomedical research in recent years. 🩺 Ipsos supports the development and monitors the evolution of treatments in rare diseases – and we thank the rare disease community for their participation in our research programs! #rarediseaseday #raredisease #biotech #pharmaceutical #digitalhealth #IpsosRareDiseaseCOE #corticobasaldegeneration #mctd #degenerativemyelopathy
-
Medical Writer & Market Research Consultant | Delivering Clear, Concise, Actionable Insights in Pharma & Biotech
Mounjaro beats Ozempic, so what? A recent JAMA study (1) that showed that Mounjaro (tirzepatide) might be more effective than Ozempic (semaglutide) in promoting weight loss among patients with type 2 diabetes and obesity. In response to this study, Dr. F. Perry Wilson, in a Medscape commentary (2), explains how non-clinical factors like insurance coverage, drug costs, and clinical familiarity significantly impact prescribing practices. While efficacy and drug profiles provide a basis for choosing a medication, the actual decision often involves navigating external constraints such as formulary restrictions or the physician's comfort and experience with the drug. 1. https://lnkd.in/eU6zTQ82 2. https://lnkd.in/eHzCsu9n
Mounjaro Beats Ozempic, So Why Isn't It More Popular?
medscape.com
-
Drug repurposing for rare diseases: Real-world data (RWD) plays a crucial role in drug repurposing by providing insights into the safety, effectiveness, and usage patterns of existing drugs in diverse patient populations. #rarediseases #treatment #RWD #RWE #drugs
Drug repurposing for rare: progress and opportunities for the rare disease community
frontiersin.org
-
🌟 Raynaud's Disease Market: Empowering Patients with Innovative Solutions ❄️ 🚀 Opportunities in the Raynaud's Disease Market: Advanced Pharmacotherapies: With the prevalence of Raynaud's disease on the rise, there is an opportunity to develop advanced pharmacotherapies, including vasodilators, calcium channel blockers, and endothelin receptor antagonists, to improve symptom management, prevent digital ischemia, and enhance quality of life for patients. Non-Pharmacological Interventions: Exploring non-pharmacological interventions, such as lifestyle modifications, behavioral therapies, and temperature regulation techniques, presents opportunities to empower patients with self-management strategies, reduce the frequency and severity of Raynaud's attacks, and minimize the impact of symptoms on daily functioning. 👉🏻 Discover the Latest Insights: Navigating Trends and Opportunities in the Raynaud's Disease Market - https://bit.ly/4aTsUtt Key players: Sanofi,GSK,Teva Pharmaceuticals.,Mylan Pharmaceuticals ULC.,Sandoz International GmbH 🔗 #RaynaudsDisease #VascularHealth #SymptomManagement #DigitalHealth #PatientEmpowerment ❄️
-
Sr. Scientist at Thermo Fisher Scientific, formerly PPD
1moA problem created directly by the drug war. People who want to use drugs are going to use drugs. Better to let them get those drugs from a controlled and regulated source than the black market where one could be putting anything into their body. An addict under medical oversight allowed to work can be a rather high functioning productive member of society, while the addict forced to the black market and given no opportunity to do honest work will become a criminal, probably OD, and cost significantly more in taxes to deal with in the long run than it would be to drop the stigma and give people the resources they need to avoid hopelessness.